Log in

NASDAQ:CARA - Cara Therapeutics Stock Price, Forecast & News

$16.35
-0.52 (-3.08 %)
(As of 12/12/2019 08:25 AM ET)
Today's Range
$16.27
Now: $16.35
$16.90
50-Day Range
$16.13
MA: $21.06
$25.98
52-Week Range
$12.19
Now: $16.35
$27.55
Volume602,545 shs
Average Volume953,758 shs
Market Capitalization$654.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.47 million
Book Value$3.38 per share

Profitability

Net Income$-74,010,000.00
Net Margins-470.70%

Miscellaneous

Employees55
Market Cap$654.49 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.


Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.15. The biopharmaceutical company had revenue of $5.79 million for the quarter, compared to analysts' expectations of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. View Cara Therapeutics' Earnings History.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Cara Therapeutics.

What price target have analysts set for CARA?

8 brokerages have issued 12-month price targets for Cara Therapeutics' stock. Their forecasts range from $13.36 to $39.00. On average, they anticipate Cara Therapeutics' share price to reach $27.60 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

What is the consensus analysts' recommendation for Cara Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (10/8/2019)
  • 2. HC Wainwright analysts commented, "Our $28 price target (from $26) is based on an overall 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and further risk-discount oral Korsuva sales in Stage 3-5 CKD. The latter oral component’s $100M peak sales in our model reflects still a conservative 40% probability of success ($300M de-risked). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028." (5/29/2019)

Has Cara Therapeutics been receiving favorable news coverage?

Media coverage about CARA stock has been trending negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cara Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Cara Therapeutics.

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)
  • Dr. Joana Goncalves, Chief Medical Officer (Age 45)
  • Dr. Joseph Stauffer, Consultant (Age 53)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67)

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.31%), Disciplined Growth Investors Inc. MN (2.10%), Point72 Asset Management L.P. (0.38%), California Public Employees Retirement System (0.25%), Alps Advisors Inc. (0.23%) and California State Teachers Retirement System (0.16%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, SG Americas Securities LLC, Rothschild Investment Corp IL and Exane Derivatives. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

Which major investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Barclays PLC, First Allied Advisory Services Inc., California Public Employees Retirement System, Squarepoint Ops LLC, Penserra Capital Management LLC, Alps Advisors Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Cara Therapeutics.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $16.35.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $654.49 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.


MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  591 (Vote Outperform)
Underperform Votes:  322 (Vote Underperform)
Total Votes:  913
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: What is the balance sheet?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel